Multiple Sclerosis. Multiple sclerosis
Conditions
Interventions
Intervention 1: Intervention group: Intervention group: The intervention group receives two 90 mg capsules of ellagic acid daily for 12 weeks before lunch and dinner (made by Exir Gostar Company). Int
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: Patient informed consent Disease diagnosis based on McDonald's criteria and MRI by a neurologist EDSS score less than 5.5 Relapsing-remitting status of the disease age between 18 and 55 years
Exclusion criteria
Exclusion criteria: Reluctance to participate in the study Take nutritional supplements, antioxidants, and ellagic acid during a month before the start of the study and during the study (except for routine supplements that are part of the treatment plan for all patients, including vitamin D) Taking nonsteroidal anti-inflammatory drugs, estrogen, progesterone, immunosuppressives, diuretics, and corticosteroids during a month before the study Patients with inflammatory bowel disease (IBD), rheumatoid arthritis, systemic lupus erythematosus, type 1 diabetes, and other autoimmune diseases are excluded from the study. Pregnancy and lactation Drug abuse
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expanded Disability Status Scale. Timepoint: At the beginning of the study and 12 weeks after supplementation with ellagic acid. Method of measurement: Extensive Disability Scale Questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Interleukin 17. Timepoint: At the beginning of the study and 12 weeks after supplementation with ellagic acid. Method of measurement: Interleukin 17 kit by ELISA method.;Interleukin 4. Timepoint: At the beginning of the study and 12 weeks after supplementation with ellagic acid. Method of measurement: Interleukin 4 kit by ELISA method.;Transforming growth factor beta (TGF-ß). Timepoint: At the beginning of the study and 12 weeks after supplementation with ellagic acid. Method of measurement: TGF-ß kit by ELISA method.;Interferon gamma. Timepoint: At the beginning of the study and 12 weeks after supplementation with ellagic acid. Method of measurement: Interferon gamma kit by ELISA method.;T-bet gene expression. Timepoint: At the beginning of the study and 12 weeks after supplementation with ellagic acid. Method of measurement: Standard quantitative real - time PCR.;GATA3 gene expression. Timepoint: At the beginning of the study and 12 weeks after supplementation with ellagic acid. Method of measurement: Standard quantitative real - time PCR.;ROR?t gene expression. Timepoint: At the beginning of the study and 12 weeks after supplementation with ellagic acid. Method of measurement: Standard quantitative real - time PCR. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Naheed Aryaeian
Iran University of Medical Sciences
Outcome results
None listed